LPCUF (Lee's Pharmaceutical Holdings) Cash Ratio: 0.32 (As of Jun. 2026) — 20% Below Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LPCUF Lee's Pharmaceutical Holdings Ltd LPCUF
74 GF Score
Price $0.19
GF Value $0.28
! 5 Warning Signs
View Full Analysis

What is Lee's Pharmaceutical Holdings Cash Ratio?

Lee's Pharmaceutical Holdings LPCUF 74 Cash Ratio is 0.32 as of Jun. 2026, which is 20% below its 10-year median of 0.40. GuruFocus rates LPCUF with a GF Score™ of 74/100 and a GF Value™ of $0.28. The stock has 5 warning signs investors should review. Among 967 Drug Manufacturers companies, Lee's Pharmaceutical Holdings ranks worse than 64.43% on this metric.

The Cash Ratio measures a company’s ability to meet its short-term obligations with cash and near-cash resources. It is calculated as a company's Cash, Cash Equivalents, Marketable Securities divides by its Total Current Liabilities. Lee's Pharmaceutical Holdings's Cash Ratio for the quarter that ended in Jun. 2026 was 0.32.

Lee's Pharmaceutical Holdings has a Cash Ratio of 0.32. It indicates that there are more current liabilities than Cash, Cash Equivalents, Marketable Securities, and the company does not have sufficient cash on hand to pay off its short-term debt.

The historical rank and industry rank for Lee's Pharmaceutical Holdings's Cash Ratio or its related term are showing as below:

LPCUF' s Cash Ratio Range Over the Past 10 Years
Min: 0.23   Med: 0.4   Max: 1.41
Current: 0.32

During the past 13 years, Lee's Pharmaceutical Holdings's highest Cash Ratio was 1.41. The lowest was 0.23. And the median was 0.40.

LPCUF's Cash Ratio is ranked worse than
64.43% of 967 companies
in the Drug Manufacturers industry
Industry Median: 0.57 vs LPCUF: 0.32

Lee's Pharmaceutical Holdings  (OTCPK:LPCUF) Cash Ratio Explanation

The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.

The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.

In general, the higher the cash ratio, the better the company's liquidity position.


Lee's Pharmaceutical Holdings Cash Ratio Related Terms


Lee's Pharmaceutical Holdings Cash Ratio Historical Data

* Premium members only.

The historical data trend for Lee's Pharmaceutical Holdings's Cash Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lee's Pharmaceutical Holdings Cash Ratio Chart

Lee's Pharmaceutical Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cash Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.30 0.29 0.26 0.28 0.31

Lee's Pharmaceutical Holdings Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Cash Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.31 0.28 0.37 0.31 0.32

LPCUF vs ZTS: Cash Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Lee's Pharmaceutical Holdings's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lee's Pharmaceutical Holdings Cash Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Lee's Pharmaceutical Holdings's Cash Ratio distribution charts can be found below:

* The bar in red indicates where Lee's Pharmaceutical Holdings's Cash Ratio falls into.


LPCUF
74GF Score
Lee's Pharmaceutical Holdings Ltd LPCUF
Cash Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lee's Pharmaceutical Holdings Cash Ratio Calculation

The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.

Lee's Pharmaceutical Holdings's Cash Ratio for the fiscal year that ended in Dec. 2025 is calculated as:

Cash Ratio (A: Dec. 2025 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=44.969/145.255
=0.31

Lee's Pharmaceutical Holdings's Cash Ratio for the quarter that ended in Jun. 2026 is calculated as:

Cash Ratio (Q: Jun. 2026 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=46.492/144.74
=0.32

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Cash Ratio →
What does a Cash Ratio of 0.32 mean?
Lee's Pharmaceutical Holdings (LPCUF) has a Cash Ratio of 0.32 as of Jun. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Lee's Pharmaceutical Holdings and its competitors. This is 20% below median its historical median of 0.40. Over the past decade, Lee's Pharmaceutical Holdings' Cash Ratio has ranged from 0.23 to 1.41. According to the industry distribution chart, Lee's Pharmaceutical Holdings ranks #623 out of 967 companies in the Drug Manufacturers industry, placing it in the top 64.4%.
Is Lee's Pharmaceutical Holdings' Cash Ratio too high?
Lee's Pharmaceutical Holdings' current Cash Ratio of 0.32 is 20% below median its 10-year median of 0.40. Over the past 10 years, this metric has ranged from a low of 0.23 to a high of 1.41. The Drug Manufacturers industry median Cash Ratio is 0.57. Lee's Pharmaceutical Holdings' value of 0.32 is 43.9% below this industry median. Based on the distribution chart, Lee's Pharmaceutical Holdings ranks #623 out of 967 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Lee's Pharmaceutical Holdings has a GF Score™ of 74/100, reflecting its overall financial health beyond just this single metric.
How does Lee's Pharmaceutical Holdings' Cash Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Lee's Pharmaceutical Holdings ranks #623 out of 967 companies for Cash Ratio. This places Lee's Pharmaceutical Holdings in the lower half of its industry. The industry median Cash Ratio is 0.57. Lee's Pharmaceutical Holdings' value of 0.32 is 43.9% below this benchmark. Historically, Lee's Pharmaceutical Holdings' own Cash Ratio has ranged from 0.23 to 1.41 over the past decade. While the company's 10-year median is 0.40 vs. the industry median of 0.57, Lee's Pharmaceutical Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Drug Manufacturers company?
The median Cash Ratio among Drug Manufacturers companies is 0.57, based on 967 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lee's Pharmaceutical Holdings's current Cash Ratio of 0.32 is 43.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Lee's Pharmaceutical Holdings and its competitors. For the Drug Manufacturers industry, the median Cash Ratio is 0.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lee's Pharmaceutical Holdings's current Cash Ratio is 0.32, which is 20% below median its own 10-year median of 0.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lee's Pharmaceutical Holdings stock overvalued right now?
Lee's Pharmaceutical Holdings (LPCUF) has a current Cash Ratio of 0.32. The stock's GF Value™ is $0.28, compared to a current price of $0.19 — trading 32% below its estimated fair value. The current Cash Ratio is 0.32, which is 20% below median its 10-year median of 0.40 and 43.9% below the Drug Manufacturers industry median of 0.57. Lee's Pharmaceutical Holdings' overall GF Score™ is 74/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Lee's Pharmaceutical Holdings (LPCUF), the current Cash Ratio is 0.32 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lee's Pharmaceutical Holdings (LPCUF) Overvalued in 2026?

Based on GuruFocus' analysis, Lee's Pharmaceutical Holdings stock appears to be undervalued. The current stock price of $0.19 is trading 32% below its estimated GF Value™ of $0.28.

Key valuation signals for LPCUF:

  • Cash Ratio: 0.32 (20% below median its 10-year median of 0.40)
  • GF Value™: $0.28 vs. price of $0.19 (32% below fair value)
  • GF Score™: 74/100 with 5 warning signs
  • Industry Position: 43.9% below the Drug Manufacturers median (#623 of 967)

No single metric tells the full story. See the LPCUF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Lee's Pharmaceutical Holdings Business Description

Other Exchanges 00950:Hong Kong
Address Hong Kong Science Park, 1st Floor, Building 20E, Phase 3, Shatin, Hong Kong, HKG
Lee's Pharmaceutical Holdings Ltd is a research-driven and market-oriented biopharmaceutical company. Along with its subsidiaries, it develops, manufactures, sells, and markets pharmaceutical products. It focuses on cardiovascular, women's health, pediatrics, rare diseases, oncology, dermatology, and obstetrics. The company's reportable segments are; Proprietary and generic products which generates key revenue; and Licensed-in products. The Proprietary Products portfolio includes Livaracine, Yallaferon, Slounase, and Nadroparin Calcium Injection. Its Licensed-in Products include Centraxal Plus, Dicoflor, Ferplex, and Natulan among others. Geographically, the company generates a majority of its revenue from the People's Republic of China.
74GF Score

Get the complete analysis for LPCUF

Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.19
Price
$0.28
GF Value